Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Rucaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms TRIUMPH
- 28 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.